- Home
- EUDA vs PLX Comparison
EUDA vs PLX Comparison
Compare EUDA & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EUDA
- PLX
- Stock Information
- Founded
- EUDA 2021
- PLX 1993
- Country
- EUDA Singapore
- PLX Israel
- Employees
- EUDA N/A
- PLX N/A
- Industry
- EUDA Blank Checks
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EUDA Finance
- PLX Health Care
- Exchange
- EUDA Nasdaq
- PLX Nasdaq
- Market Cap
- EUDA 149.4M
- PLX 160.2M
- IPO Year
- EUDA N/A
- PLX 1998
- Fundamental
- Price
- EUDA $3.76
- PLX $2.33
- Analyst Decision
- EUDA
- PLX
- Analyst Count
- EUDA 0
- PLX 0
- Target Price
- EUDA N/A
- PLX N/A
- AVG Volume (30 Days)
- EUDA 102.6K
- PLX 553.9K
- Earning Date
- EUDA 01-01-0001
- PLX 03-13-2025
- Dividend Yield
- EUDA N/A
- PLX N/A
- EPS Growth
- EUDA N/A
- PLX N/A
- EPS
- EUDA N/A
- PLX N/A
- Revenue
- EUDA $3,811,496.00
- PLX $45,667,000.00
- Revenue This Year
- EUDA $121.80
- PLX N/A
- Revenue Next Year
- EUDA $78.17
- PLX $90.00
- P/E Ratio
- EUDA N/A
- PLX N/A
- Revenue Growth
- EUDA N/A
- PLX N/A
- 52 Week Low
- EUDA $1.20
- PLX $0.82
- 52 Week High
- EUDA $6.30
- PLX $2.36
- Technical
- Relative Strength Index (RSI)
- EUDA 40.49
- PLX 78.72
- Support Level
- EUDA $3.55
- PLX $2.11
- Resistance Level
- EUDA $3.93
- PLX $2.36
- Average True Range (ATR)
- EUDA 0.34
- PLX 0.12
- MACD
- EUDA -0.09
- PLX 0.00
- Stochastic Oscillator
- EUDA 19.66
- PLX 94.23
About EUDA EUDA Health Holdings Limited
EUDA Health Holdings Ltd is a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem aimed at making healthcare affordable and accessible, The company's proprietary unified AI platform quickly assesses a patient's medical history, triages a condition, digitally connects patients with clinicians, and predicts optimal treatment outcomes. The company caters to all stages of care, including wellness and prevention, urgent care and emergencies, pre-existing conditions, and aftercare services. The company operates in two segments namely Medical services and property management services, out of which the company derives its maximum revenue from Medical services.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.